Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL) (REMOVAL)

This study is ongoing, but not recruiting participants.
NHS Greater Glasgow and Clyde
Juvenile Diabetes Research Foundation
Imperial College London
University of Wisconsin, Madison
University of Dundee
Merck Serono S.A., Geneva
Itamar-Medical, Israel
University of Western Ontario, Canada
University of Melbourne
Steno Diabetes Center
Maastricht University Medical Center
Information provided by (Responsible Party):
Prof John Petrie, University of Glasgow Identifier:
First received: November 23, 2011
Last updated: May 20, 2015
Last verified: May 2015
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: July 2017
  Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)